Lucitanib Clinical Development Overview
Lucitanib, an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Clovis has global rights (excluding China) for lucitanib.
Recent data for a drug that inhibits these same three pathways - when combined with a PD-1 inhibitor - are extremely encouraging and represent a scientific rationale for the development of lucitanib in combination with a PD-1 inhibitor, and a Clovis-sponsored Phase 1b/2 study of lucitanib in combination with nivolumab in advanced gynecologic cancers and other solid tumors is currently enrolling. Based on encouraging data of VEGF and PARP inhibitors in combination, a Phase 1b/2 study of lucitanib in combination with rucaparib in advanced ovarian cancer is also enrolling as an arm of the SEASTAR study. Initial data are anticipated at medical meetings beginning in mid-2020.
Lucitanib Scientific Presentations
Combination of the Angiogenesis Inhibitor Lucitanib with Immune Checkpoint Blockade Augments Anti-tumor Activity in Syngeneic Models
Presented at 2019 SITCDownload the PDF